13 July 2022>: Clinical Research
Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland
Iwona Homa-Mlak 1ACDEF* , Marcin Mazurek 1BCEF , Aleksandra Majdan 1DEF , Radosław Mlak 1ACDE , Maria Majdan 2ADEF , Teresa Mełecka-Massalska 1ADEFDOI: 10.12659/MSM.936534
Med Sci Monit 2022; 28:e936534
Table 1 General characteristic of the study group.
Variable | n (%) or median (range) | |
---|---|---|
Study group (n=59) | Control group (n=52) | |
Male | 8 (13.56%) | 8 (15.38%) |
Female | 51 (86.44%) | 44 (84.62%) |
Age (years) | 36.5 (19–72) | 38.0 (22–64) |
Duration of the disease (years) | 6 (0–37) | – |
SLEDAI | ||
Mild | 51 (86.4%) | – |
Moderate | 6 (10.17%) | – |
Severe | 2 (3.39%) | – |
n – number, SLEDAI – Systemic Lupus Erythematosus Disease Activity Index. |